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Objective. Baricitinib is an orally administered
inhibitor of JAK1 and JAK2 that has been shown to be
effective in treating rheumatoid arthritis (RA). This study
was undertaken to analyze changes in lymphocyte cell
subsets during baricitinib treatment and to correlate
these changes with clinical outcomes.
Methods. An integrated analysis was conducted by
pooling data from 3 completed phase III trials comparing
placebo with baricitinib treatment (RA-BEAM, RA-
BUILD, and RA-BEACON) and 1 ongoing long-term
extension study (RA-BEYOND) in patients with active RA
(n = 2,186).
Results. Baricitinib treatment was associated with
an early transient increase in total lymphocyte count at
week 4, which returned to baseline by week 12. Transient
changes within normal reference ranges in Tcells and sub-
sets were observed with baricitinib treatment, up to week
104. B cells and relevant subpopulations increased after 4
weeks of baricitinib treatment, with no further increases
noted through 104 weeks of treatment. Natural killer
(NK) cells temporarily increased after 4 weeks of barici-
tinib treatment, before decreasing below baseline levels
and then stabilizing over time. With baricitinib treatment,
few correlations were observed between changes in lym-
phocyte subsets and clinical end points, and most correla-
tions were also observed within the placebo group. A
modest potential association between low NK cell numbers
and treatment-emergent infections was observed in the
baricitinib 4 mg/day treatment group, but not for serious
infections or herpes zoster.
Conclusion. Overall, these findings demonstrate
that changes in lymphocyte subsets were largely within
normal reference ranges across the baricitinib phase III
RA clinical program and were not associated with in-
creased risk of serious infections.
Targeted synthetic disease-modifying antirheumatic
drugs (DMARDs) are orally available low molecular weight
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molecules developed for the treatment of rheumatoid
arthritis (RA). Recent additions to this drug class include
JAK inhibitors, which target cytokine signaling pathways
implicated in RA pathogenesis (1–5).
Baricitinib is a selective JAK1/JAK2 inhibitor (6)
approved for the treatment of moderate-to-severe RA in
adults in >40 countries including multiple European coun-
tries, Japan, and the United States. Phase III trials
showed significant clinical efficacy of baricitinib in
patients with active RA who were naive to conventional
synthetic DMARDs (csDMARDs) or had inadequate
responses to csDMARDs or biologic DMARDs (7–10).
Baricitinib was associated with significant clinical
improvement compared to placebo (which typically was
given along with stable background csDMARDs), and
compared to the tumor necrosis factor (TNF) inhibitor
adalimumab in the RA-BEAM trial (7,8,10).
Baricitinib, along with other JAK inhibitors, has
been shown to change circulating lymphocyte subset pop-
ulations, largely within normal ranges (11–13). However,
detailed analyses of effects on subsets are lacking, and
their relevance to efficacy and safety is unclear (14). This
study demonstrated changes in lymphocyte numbers,
including subpopulations, during treatment in patients
with active RA (n = 2,186). It comprised an integrated
analysis of 3 completed phase III RA trials comparing pla-
cebo treatment to baricitinib treatment (RA-BEAM, RA-
BUILD, and RA-BEACON), and 1 ongoing phase III
long-term extension study (RA-BEYOND) (7,8,10). This
study also tested whether changes in lymphocyte subsets
were associated with efficacy or adverse events.
PATIENTS AND METHODS
Patients and study designs. We examined data from 3
previously reported randomized, double-blind, multicenter phase
III trials (RA-BEAM, RA-BUILD, and RA-BEACON) and 1
ongoing phase III long-term extension study (RA-BEYOND)
with data up to January 1, 2016. Patients were ≥18 years of age
with moderate-to-severe active RA. Descriptions of the patient
cohorts for each of the trials are shown in Supplementary Table 1
(available on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.40680/abstract), and de-
tailed methods were reported previously (7,8,10). Criteria for
exclusion and permanent discontinuation included an abnormal
lymphocyte count of <750 cells/ll and <200 cells/ll, respectively.
After completion of 1 of the 3 randomized trials,
patients could enter the RA-BEYOND study and receive either
baricitinib 2 mg/day or 4 mg/day for up to 60 months. Patients
entering RA-BEYOND after 52 weeks in RA-BEAM continued
baricitinib 4 mg/day or switched to baricitinib 4 mg/day from
adalimumab. Patients entering RA-BEYOND after 24 weeks of
treatment in RA-BUILD or RA-BEACON continued baricitinib
2 mg/day or 4 mg/day, or switched to baricitinib 4 mg/day from
placebo. In RA-BEYOND, patients who received baricitinib
4 mg/day for ≥15 months (including in the preceding originator
trial) without rescue and achieved sustained low disease activity
or remission were re-randomized (under blinded conditions) to
either continue baricitinib 4 mg/day or step down to baricitinib 2
mg/day. Studies were conducted in accordance with the ethical
principles of the Declaration of Helsinki and Good Clinical
Practice guidelines and were approved by the ethics committee
or institutional review board of each center. All patients pro-
vided written informed consent.
Analytical methodology. Whole blood samples were col-
lected at week 0 (for placebo, n = 856–892; for baricitinib 2 mg/
day, n = 392–403; for baricitinib 4 mg/day, n = 869–891), week 4
(placebo, n = 747–825; 2 mg/day, n = 358–384; 4 mg/day, n =
765–846), week 12 (placebo, n = 706–790; 2 mg/day, n = 348–361;
4 mg/day, n = 755–835), weeks 24–32 (placebo, n = 481–530;
2 mg/day, n = 272–295; 4 mg/day, n = 637–706), weeks 48–52
(2 mg/day, n = 182–196; 4 mg/day, n = 364–582), and weeks 96–
104 (2 mg/day, n = 79–91; 4 mg/day, n = 120–135). Total lympho-
cyte count was analyzed using a Beckman Coulter cell counter.
Lymphocyte subsets were analyzed using a BD FACSCanto II
flow cytometer (BD Biosciences) and a previously optimized
panel (15) (see Supplementary Table 2, available on the Arthritis
& Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.
1002/art.40680/abstract). Data on Th1 and Th17 cells at the 96–
104-week time point were not acquired, and data on these subsets
in the baricitinib 2 mg/day group were not available for the 48–
52-week time point due to an insufficient sample size. T cells,
including CD4 and CD8 subpopulations, B cells, and natural
killer (NK) cells, were identified using BD Multitest 6-color
TBNK reagent (BD Biosciences). A Human FoxP3 Buffer Set
(BD Biosciences) was used to identify Treg cells. Additional flow
cytometry methods and representative gating for cell subsets in
the primary flow cytometry data are included in Supplementary
Figures 1–4 and Supplementary Flow Cytometry Methods (http://
onlinelibrary.wiley.com/doi/10.1002/art.40680/abstract).
Statistical analysis. An integrated data set was gener-
ated by pooling patient data from RA-BEAM, RA-BUILD, RA-
BEACON, and RA-BEYOND. The placebo group came from
RA-BEAM, RA-BUILD, and RA-BEACON; data were cen-
sored at rescue or the end of the 24-week placebo treatment pe-
riod. The baricitinib 2 mg/day group came from RA-BUILD and
RA-BEACON, with associated data from RA-BEYOND; data
were censored at rescue. The baricitinib 4 mg/day group came
from RA-BEAM, RA-BUILD, and RA-BEACON, with associ-
ated data from RA-BEYOND; data were censored at rescue or
dose step-down.
For changes in lymphocyte subsets, a restricted maxi-
mum-likelihood–based mixed model for repeated measures was
used, which included treatment, visit, and treatment-by-visit inter-
action as fixed categorical effects and baseline as fixed continuous
effects. Change from baseline was estimated by modeling 4
covariance structures (autoregressive, heterogeneous autoregres-
sive, compound symmetry, and Toeplitz matrix) and selecting the
variance–covariance structure with the smallest Akaike informa-
tion criterion. Fisher’s exact test was used for comparisons of inci-
dence of treatment-emergent (TE) infections between treatment
groups by NK cell count category.
For rheumatoid factor (RF) and anti–citrullinated pro-
tein antibody (ACPA), mean changes from baseline were com-
pared between treatment groups by analysis of covariance, with
treatment and baseline values as covariates. Type III sums of
squares were used for comparisons of each baricitinib dose to
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placebo, and least squares means, SEM, and P values were
reported.
The weighted Pearson’s correlation coefficient and its
associated P value were used to test whether correlations
between change from baseline in lymphocyte subset and Disease
Activity Score in 28 joints (16) based on the high-sensitivity C-
reactive protein level (DAS28-hsCRP) were significant by treat-
ment group.
RESULTS
Changes in lymphocyte subsets. Total lymphocyte
count increased transiently at week 4 with baricitinib 2
mg/day and 4 mg/day compared to placebo, returning to
baseline by week 12 and remaining stable thereafter (Fig-
ure 1). At baseline, low lymphocyte counts were observed
in 8.7%, 6.2%, and 6.6% of patients receiving placebo,
baricitinib 2 mg/day, and baricitinib 4 mg/day, respec-
tively, and high lymphocyte counts were observed in
4.3%, 4.7%, and 4.0% of patients. Based on 24 weeks of
data up to rescue, the proportions of patients with ≥1 TE
low lymphocyte count were 10.7%, 8.2%, and 8.9% with
placebo, baricitinib 2 mg/day, and baricitinib 4 mg/day,
respectively, and the proportions of patients with ≥1 TE
high lymphocyte count were 4.4%, 11.2%, and 11.9%,
respectively (Figure 1).
CD3+, CD4+, and CD8+ T cell counts were
increased at week 4 with baricitinib 2 mg/day and 4 mg/
day compared to placebo, and returned to baseline by
week 12. Inconsistent changes in these Tcell subsets were
observed at weeks 24–32 (Figures 2A–C) but were trend-
ing downward compared to baseline. At baseline, low
CD3+ T cell counts were observed in 11.3%, 9.3%, and
9.1% of patients receiving placebo, baricitinib 2 mg/day,
and baricitinib 4 mg/day, respectively; low CD4+ T cell
counts were observed in 14.2%, 13.4%, and 13.5% of
patients; low CD8+ T cell counts were observed in 7.9%,
7.6%, and 6.4% of patients. Based on 24 weeks of data up
to rescue, the proportions of patients with ≥1 TE low
CD3+, CD4+, or CD8+ Tcell count did not differ between
baricitinib and placebo treatments (Figures 2A–C).
Th1 (CD4+CXCR3+CCR6) cell counts were
increased at week 4 with baricitinib treatment and were
decreased below baseline through weeks 24–32 (Figure 2D).
Th17 (CD4+CXCR3CCR6+) cell counts increased at
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Figure 1. Top, Total lymphocyte counts during treatment. Values are the median and 25th–75th percentiles. Bottom, Patients with treatment-
emergent low lymphocyte count (TE low) and with treatment-emergent high lymphocyte count (TE high). Values are the number (%) of the
number at risk (NAR). *** = P ≤ 0.001 versus placebo, based on the least squares mean difference change from baseline. ULN = upper limit of
normal; LLN = lower limit of normal.
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Figure 2. T cell counts during treatment. Counts of CD3+ cells (A), CD4+ cells (B), CD8+ cells (C), Th1 cells (D), Th17 cells (E), and Treg cells
(F) are shown. Values are the median and 25th–75th percentiles. A–C include patients with TE high T cell count and TE low T cell count. Values
are the number (%) of the NAR. * = P ≤ 0.05; ** = P ≤ 0.01; *** = P ≤ 0.001 versus placebo, based on the least squares mean difference change
from baseline. See Figure 1 for definitions.
1926 TANAKA ET AL
Abnormality
Placebo
(N=892)
Baricitinib 2-mg
(N=403)
Baricitinib 4-mg
(N=891)
TE Low
NAR
n (%)
569
57 (10.0)
293
11 (3.8)
604
22 (3.6)
TE High
NAR
n (%)
838
10 (1.2)
383
14 (3.7)
841
44 (5.2)
Week
401-6925-8423-422140
C
D
19
+ 
B 
C
el
l C
ou
nt
 (c
el
ls
/µ
L)
0
100
200
300
400
500
600
700
Placebo
Baricitinib 2-mg
Baricitinib 4-mg
ULN
LLN
***
***
***
***
*
***
Week
401-6925-8423-422140
Sw
itc
he
d 
M
em
or
y 
B 
C
el
l C
ou
nt
 (c
el
ls
/µ
L)
0
25
50
75
Placebo
Baricitinib 2-mg
Baricitinib 4-mg
***
***
***
***
***
***
Week
401-6925-8423-422140N
on
-S
w
itc
he
d 
M
em
or
y 
B 
C
el
l C
ou
nt
 (c
el
ls
/µ
L)
0
10
20
30
40
50
Placebo
Baricitinib 2-mg
Baricitinib 4-mg
***
***
***
***
***
***
Week
401-6925-8423-422140
M
at
ur
e 
N
aï
ve
 B
 C
el
l C
ou
nt
 (c
el
ls
/µ
L)
0
50
100
150
200
250
300
Placebo
Baricitinib 2-mg
Baricitinib 4-mg***
***
***
***
*
***
Week
401-6925-8423-422140
Im
m
at
ur
e 
Tr
an
si
tio
na
l B
 C
el
l C
ou
nt
 (c
el
ls
/µ
L)
0
5
10
15
20
Placebo
Baricitinib 2-mg
Baricitinib 4-mg
***
***
***
***
***
***
BA
C
E
D
Figure 3. B cell counts during treatment. Counts of CD19+ B cells (A), switched memory B cells (B), non-switched memory B cells (C), mature
naive B cells (D), and immature transitional B cells (E) are shown. Values are the median and 25th–75th percentiles. A includes patients with TE
high B cell count and TE low B cell count. Values are the number (%) of the NAR. * = P ≤ 0.05; *** = P ≤ 0.001 versus placebo, based on the
least squares mean difference change from baseline. See Figure 1 for definitions.
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week 4 with baricitinib treatment, returned to baseline by
week 12 with baricitinib 4 mg/day, and decreased at weeks
24–32 with baricitinib 2 mg/day (Figure 2E). Compared to
the placebo group, which exhibited a modest increase at
week 12, Treg cell counts were decreased at week 12 in both
baricitinib groups and returned to near baseline by weeks
24–32, remaining stable thereafter (Figure 2F). For CD3+,
CD4+, and CD8+ T cells, within-group analysis demon-
strated a significant decrease from baseline by weeks 96–104
with baricitinib 2 mg/day and 4 mg/day. For Th1 cells, a sig-
nificant decrease from baseline by weeks 48–52 was
observed with baricitinib 4 mg/day (Figures 2A–D).
CD19+ B cells and B cell subpopulations (including
switched memory, non-switched memory, mature naive,
and immature transitional B cells) were significantly
increased at weeks 4 through 24–32 in both baricitinib
groups compared to placebo, and remained slightly above
baseline or gradually returned to baseline over time (Fig-
ures 3A–E). At baseline, high CD19+ B cell counts were
observed in 3.5%, 3.3%, and 3.6% of patients who received
placebo, baricitinib 2 mg/day, and baricitinib 4 mg/day,
respectively. Based on 24 weeks of data up to rescue, the
proportions of patients with ≥1 TE high CD19+ B cell
count were 1.2%, 3.7%, and 5.2% (Figure 3A).
Finally, NK cell counts were increased significantly
by week 4 with baricitinib compared to placebo; changes
were transient, and NK cell counts were decreased by
weeks 12 through 24–32 in both baricitinib groups (Fig-
ure 4). In within-group analysis, NK cell counts in patients
treated with baricitinib 2 mg/day and 4 mg/day were below
baseline at the week 12 through weeks 48–52 assessment
(P ≤ 0.05). While NK cell counts in patients treated with
baricitinib 4 mg/day were below baseline by the weeks 96–
104 assessment, the change from baseline for patients
receiving 2 mg/day (P > 0.05) was no longer significant by
this point (Figure 4). At baseline, low NK cell counts were
observed in 15.1%, 11.1%, and 14.9% of patients receiv-
ing placebo, baricitinib 2 mg/day, and baricitinib 4 mg/day,
respectively. The proportions of patients with ≥1 TE low
NK cell count were 9.9%, 14.8%, and 20.4% (Figure 4).
Among patients with a TE low NK cell count at their last
visit (while receiving baricitinib) who had a follow-up
value available (n = 16), the count normalized during the
posttreatment follow-up period in 11 patients (69%).
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Figure 4. Top, Natural killer (NK) cell count during treatment. Values are the median and 25th–75th percentiles. Bottom, Patients with TE low
NK cell count and with TE high NK cell count. Values are the number (%) of the NAR. *** = P ≤ 0.001 versus placebo, based on the least
squares mean difference change from baseline. See Figure 1 for other definitions.
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Changes in lymphocyte counts and clinical effects
of baricitinib treatment. Negative correlations between
changes from baseline in the DAS28-hsCRP and counts of
CD19+ B cell and several B cell subpopulations were
observed with placebo and baricitinib treatment, indicating
larger improvements in the DAS28-hsCRP with larger
increases in B cell counts (see Supplementary Table 3,
available on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.40680/abstract). A
negative correlation was also observed between changes in
the DAS28-hsCRP and counts of Th17 and Treg cells with
baricitinib 4 mg/day (Supplementary Table 3). The increase
in CD19+ B cells observed with baricitinib (Figure 3A)
occurred while RF titers had significantly decreased from
baseline at week 24 with baricitinib 2 mg/day and 4 mg/day
compared to placebo, and ACPA titers were significantly
decreased from baseline at week 24 with baricitinib 4 mg/
day only (see Supplementary Table 4 at http://onlinelibrary.
wiley.com/doi/10.1002/art.40680/abstract).
Additionally, we tested whether changes in NK cell
numbers were associated with increased infection rates in
baricitinib-treated RA patients, based on 24 weeks of data
up to rescue. Compared to patients who never experi-
enced a low NK cell count during placebo treatment,
increases in frequency of overall infections were seen in
both baricitinib groups, and an increase in frequency of
herpes zoster infection was seen in the baricitinib 4 mg/
day group. However, the rate of serious infection was sim-
ilar among all 3 groups (Table 1). Patients who experi-
enced ≥1 low NK cell value during the treatment period
exhibited a dose-related increase in overall infections
with baricitinib versus placebo; herpes zoster and seri-
ous infection rates were similar among all 3 groups
(Table 1). Similar associations were observed between
changes in CD4+ T cell counts and infection rates (see
Supplementary Table 5 at http://onlinelibrary.wiley.com/
doi/10.1002/art.40680/abstract). Among patients who ex-
perienced a low NK cell count prior to their first TE
infection, the majority experienced a low NK cell count
<3 months before the infection, across treatment groups
(Supplementary Table 6).
DISCUSSION
In this study, we characterized changes in lympho-
cyte subsets in RA patients (n = 2,186) from phase III and
long-term extension trials in the baricitinib clinical pro-
gram and assessed whether observed lymphocyte changes
correlated with clinical effects of baricitinib treatment.
Changes in lymphocyte subsets were generally within the
normal range and were largely consistent across the baric-
itinib phase III RA clinical trials, which included patients
with different responsiveness to prior DMARD therapies
(11–13). In this integrated analysis, a transient increase in
total lymphocyte count was observed after 4 weeks of
treatment with baricitinib, returning to baseline by week
12. Overall changes in lymphocyte subsets from a phase
III study of baricitinib in the treatment of DMARD-naive
RA patients (RA-BEGIN) (13) generally reflected similar
patterns of change as those in this analysis. An early tran-
sient increase in lymphocyte count was also observed in
patients with plaque psoriasis who were treated with
baricitinib (17).
These findings may in part relate to the timing of
baricitinib administration. In previous phase I studies, tran-
sient increases in total lymphocyte counts were observed
within hours of baricitinib administration, returning to
baseline prior to the next daily dose (6). Transient changes
Table 1. Incidence of TE infection by NK cell count, weeks 0–24*
Placebo
(n = 860)
Baricitinib 2 mg/day
(n = 393)
Baricitinib 4 mg/day
(n = 868)
Never-low NK cell count, no. (%)† 718 (83.5) 316 (80.4) 618 (71.2)‡
Patients with ≥1 TE infection 213 (29.7) 114 (36.1)§ 217 (35.1)§
Patients with ≥1 TE herpes zoster 3 (0.4) 3 (0.9) 13 (2.1)¶
Patients with ≥1 serious infection 13 (1.8) 4 (1.3) 10 (1.6)
Low NK cell count, no. (%)# 142 (16.5) 77 (19.6) 250 (28.8)‡
Patients with ≥1 TE infection 47 (33.1) 29 (37.7) 112 (44.8)§
Patients with ≥1 TE herpes zoster 0 1 (1.3) 2 (0.8)
Patients with ≥1 serious infection 1 (0.7) 1 (1.3) 3 (1.2)
* Data are from the time of treatment initiation through 24 weeks, with data censored at rescue.
TE = treatment-emergent.
† Patients who never experienced low natural killer (NK) cell values (defined as values <95 cells/ll)
at any time postbaseline up to time of rescue.
‡ P ≤ 0.001 versus baricitinib 2 mg/day and versus placebo, by Fisher’s exact test.
§ P ≤ 0.05 versus placebo.
¶ P ≤ 0.01 versus placebo.
# Patients who experienced ≥1 low NK cell value at any time postbaseline up to the time of rescue.
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in T cells and subsets were observed with baricitinib treat-
ment, with cell counts remaining largely within normal ref-
erence ranges. While CD3+, CD4+, and CD8+ T cells
decreased below baseline by weeks 96–104, longer-term
data will be required to determine whether changes con-
tinue or a new baseline is established in patients.
We observed that B cells and subpopulations
increased after 4 weeks of baricitinib treatment and re-
mained above baseline or stabilized over time. JAK inhi-
bition modulates cytokine signaling, and therefore,
possible downstream alterations in adhesion molecule
expression and chemokine production may affect B cell
trafficking with baricitinib treatment, resulting in elevated
peripheral B cell numbers. Furthermore, differentiation
of the B cell lineage may be induced in compensation for
JAK1- and JAK2-mediated inhibition of cytokine produc-
tion, such as type I and type II interferons. Importantly,
baricitinib treatment did not result in increased autoanti-
body titers, suggesting that the increase in B cells may not
be pathologic. It is possible that some of the class-
switched memory B cells, increased by baricitinib in a
dose-dependent manner, may be regulatory B cells, which
inhibit disease activity. Further studies would be needed
to clarify these possibilities.
NK cells transiently increased after 4 weeks of
baricitinib treatment, before decreasing below baseline
levels and then gradually stabilizing over time. Notably,
baseline low NK cell counts were observed in up to 15.1%
of patients in this analysis. The overall effect of JAK1 and
JAK2 inhibition on peripheral blood mononuclear cell
subsets may potentially reflect the combined effects of a
number of different biologic processes. These include
demargination resulting from endothelial deactivation
and altered marrow production of cellular subtypes. Iden-
tifying the predominant process that results in the
observed change in peripheral blood may depend on the
half-life of the circulating cell.
Changes in lymphocyte subsets have also been
characterized with tofacitinib, a JAK inhibitor that prefer-
entially inhibits JAK1 and JAK3 (18). Phase II and phase
III clinical trials involving patients with RA treated with
tofacitinib showed a transient increase in total lympho-
cytes early in treatment, with a gradual decrease over time
(19–21). In phase II RA clinical trials, variable changes in
T cells were observed with short-term tofacitinib treat-
ment, while B cells and NK cells increased and decreased
from baseline, respectively (19,20). To our knowledge,
robust data from systematic follow-up of tofacitinib-
treated RA patients from baseline through long-term
treatment are unavailable.
Changes in lymphocyte subsets have been charac-
terized in clinical trials with other JAK inhibitors. Phase
II clinical trials involving patients with RA treated with
the selective JAK1 inhibitor filgotinib showed no clear
dose-dependent changes in the rates of TE low lympho-
cyte or NK cell counts during short-term treatment, while
similar studies with upadacitinib showed decreased lym-
phocyte and NK counts following administration of that
agent (22–25). These data suggest the possibility that dif-
ferent JAK inhibitors may be associated with slightly dif-
ferent lymphocyte changes over time, and in vitro JAK
selectivity is not an easy predictor of these changes. It
should be noted that lymphocyte subpopulations were
monitored in 2,186 patients with active RA who partici-
pated in the baricitinib phase III program, including long-
term treatment, making it the most extensive analysis of
lymphocyte subset changes with a JAK inhibitor described
to date.
Changes in lymphocyte levels have also been
reported in patients with RA who were treated with com-
pounds that target TNF or interleukin-6 (IL-6) signaling.
The phase III RA-BEAM trial, as well as other studies,
showed that the TNF inhibitor adalimumab produced a
sustained increase in total lymphocyte counts over time in
patients with RA (12,21,26). Consistent with an increase
in total lymphocyte levels over time, the RA-BEAM trial
demonstrated that adalimumab treatment also resulted in
increased T cells, B cells, and NK cells (12). Several stud-
ies with small patient populations have analyzed changes
in lymphocyte subsets in RA patients who were treated
with tocilizumab, a monoclonal antibody that inhibits the
IL-6 receptor. Two studies showed that tocilizumab treat-
ment resulted in increased Treg cells, with one study show-
ing decreased Th17 cells with treatment (27,28).
Conflicting changes in B cell numbers have been demon-
strated with tocilizumab treatment; one study showed
increased total B cells, with no significant changes in B cell
subsets, while another showed decreased levels of memory
B cell subsets (28,29). Overall, these findings demonstrate
that RA therapies that target different biologic pathways
are associated with distinct changes in lymphocyte subsets.
Taking into consideration these changes, we at-
tempted to determine, in an integrated analysis, if there
are clinical correlations between changes in lymphocyte
subsets and the DAS28-hsCRP. Negative correlations
between changes in the DAS28-hsCRP and B cell subpop-
ulations were observed with placebo and baricitinib treat-
ment. In addition, changes in the DAS28-hsCRP were
negatively correlated with Th17 and Treg cell numbers in
the baricitinib 4 mg/day group. Though statistically signifi-
cant, the strength of these associations was modest. The
increase in B cells with baricitinib treatment was not asso-
ciated with an increase in autoantibody titers. Finally,
patients who never experienced low NK cell counts as well
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as patients who experienced ≥1 low NK cell value with
baricitinib 4 mg/day experienced a small increase in the
rate of overall infection (though not serious infection).
Low NK cell counts did not correlate with the rate of her-
pes zoster infection, a known adverse reaction with barici-
tinib, suggesting that NK modulation is not a dominant
mechanism in this association.
The present findings do not mechanistically ex-
plain the observed changes in lymphocyte subsets. Several
mechanisms could contribute to the changes, operating
either in isolation or in combination. Thus, cell number
may indicate transiently increased synthesis (perhaps
reflecting an immediate effect of drug on marrow homeo-
stasis), effects on cellular mobilization from lymphoid or
inflamed tissues, effects on cellular egress from the circu-
lation, or effects on cellular survival. Moreover, the
impact of JAK inhibition is distinct in different subsets,
leading, most notably in the B cell compartment, to a new
homeostatic circulatory level. Whether these effects are
mediated directly on lymphocyte subsets via JAK-sensitive
receptors or via altered chemokine or chemokine recep-
tor expression (dependent on JAK-driven pathways) is
unclear and warrants further investigation.
A significant limitation of this study is that the
follow-up period, while considerable, does not span many
years, though RA can require lifelong treatment. Longer-
term lymphocyte subset data continue to be collected dur-
ing the ongoing long-term extension study RA-BEYOND,
which currently provides up to 5 years of treatment with
baricitinib after patients complete an originating study;
evaluation of these longer-term data, when available, will
assist in addressing this limitation.
In conclusion, this integrated analysis of lympho-
cyte subsets during the course of treatment with barici-
tinib in a large phase III RA data set has shown
distinct changes in different lymphocyte populations,
including B cell increases, variable changes in T cell
counts, and transient reduction in NK cells, without
strong association with efficacy or safety end points.
The later kinetics of these analytes during longer-term
baricitinib treatment, and any clinical correlations, con-
tinue to be evaluated.
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